Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer

Lung Cancer

Volumn 66, Issue 3, 2009, Pages 359-364

  Park, Joo Hun ^a   Choi, Ho ^a   Kim, Young Bae ^a   Kim, Young Sun ^a   Sheen, Seung Soo ^a   Choi, Jin Hyuk ^a   Lee, Hye Lim ^a   Lee, Keu Sung ^a   Chung, Woo Young ^a   Lee, Sungsoo ^a   Park, Kyung Joo ^a   Hwang, Sung Chul ^a   Lee, Kyi Beum ^a   Park, Kwang Joo ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Angiopoietin 1; Early stage; Non small cell lung cancer; Survival; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; VASCULOTROPIN;

ADULT; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENT CANCER; SURVIVAL TIME; TUMOR VASCULARIZATION;

AGED; ANGIOPOIETIN-1; ANGIOPOIETIN-2; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MALE; MICROVESSELS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350619207     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.03.002     Document Type: Article

References (39)

1. Scagliotti G. Consensus development conference on the medical treatment of non-small cell lung cancer: treatment of the early stages. Lung Cancer 38 Suppl. 3 (2002) S23-S29
2. Ost D., Goldberg J., Rolnitzky L., and Rom W.N. Survival after surgery in stage IA and IB non-small cell lung cancer. Am J Respir Crit Care Med 177 (2008) 516-523
3. Lau S.K., Boutros P.C., Pintilie M., Blackhall F.H., Zhu C.Q., Strumpf D., et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 25 (2007) 5562-5569
4. Muley T., Fetz T.H., Dienemann H., Hoffmann H., Herth F.J., Meister M., et al. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC. Lung Cancer 60 (2008) 408-415
5. Suzuki K., Nagai K., Yoshida J., Moriyama E., Nishimura M., Takahashi K., et al. Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg 67 (1999) 927-932
6. Angeletti C.A., Lucchi M., Fontanini G., Mussi A., Chella A., Ribechini A., et al. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence. Cancer 78 (1996) 409-415
7. Giatromanolaki A., Koukourakis M.I., Kakolyris S., Turley H., O'Byrne K., Scott P.A., et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 4 (1998) 3017-3024
8. Bremnes R.M., Camps C., and Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51 (2006) 143-158
9. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
10. Shim W.S., Ho I.A., and Wong P.E. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 5 (2007) 655-665
11. Yilmaz A., Ernam D., Unsal E., Demirag F., Atikcan S., and Tastepe I. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer. Arch Med Res 38 (2007) 764-768
12. Seto T., Higashiyama M., Funai H., Imamura F., Uematsu K., Seki N., et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 53 (2006) 91-96
13. Peters K.G. Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel. Circ Res 83 (1998) 342-343
14. Tait C.R., and Jones P.F. Angiopoietins in tumours: the angiogenic switch. J Pathol 204 (2004) 1-10
15. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87 (1996) 1171-1180
16. Hayes A.J., Huang W.Q., Mallah J., Yang D., Lippman M.E., and Li L.Y. Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res 58 (1999) 224-237
17. Thurston G., Suri C., Smith K., McClain J., Sato T.N., Yancopoulos G.D., et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286 (1999) 2511-2514
18. Hawighorst T., Skobe M., Streit M., Hong Y.K., Velasco P., Brown L.F., et al. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 160 (2002) 1381-1392
19. Wong M.P., Chan S.Y., Fu K.H., Leung S.Y., Cheung N., Yuen S.T., et al. The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 29 (2000) 11-22
20. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 (1997) 55-60
21. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 (1999) 1994-1998
22. Takahama M., Tsutsumi M., Tsujiuchi T., Nezu K., Kushibe K., Taniguchi S., et al. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin Cancer Res 5 (1999) 2506-2510
23. Takanami I. Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis. Oncol Rep 12 (2004) 849-853
24. Tanaka F., Ishikawa S., Yanagihara K., Miyahara R., Kawano Y., Li M., et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 62 (2002) 7124-7129
25. Caine G.J., Blann A.D., Stonelake P.S., Ryan P., and Lip G.Y. Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest 33 (2003) 883-890
26. Niedzwiecki S., Stepien T., Kopec K., Kuzdak K., Komorowski J., Krupinski R., et al. Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers. Cytokine 36 (2006) 291-295
27. Schliemann C., Bieker R., Thoennissen N., Gerss J., Liersch R., Kessler T., et al. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 21 (2007) 1901-1906
28. Park J.H., Park K.J., Kim Y.S., Sheen S.S., Lee K.S., Lee H.N., et al. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132 (2007) 200-206
29. Stratmann A., Risau W., and Plate K.H. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153 (1998) 1459-1466
30. Shirakawa K., Tsuda H., Heike Y., Kato K., Asada R., Inomata M., et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 61 (2001) 445-451
31. Wang J., Wu K., Zhang D., Tang H., Xie H., Hong L., et al. Expressions and clinical significances of angiopoietin-1,-2 and Tie2 in human gastric cancer. Biochem Biophys Res Commun 337 (2005) 386-393
32. Currie M.J., Gunningham S.P., Han C., Scott P.A., Robinson B.A., Harris A.L., et al. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling. Clin Cancer Res 7 (2001) 918-927
33. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
34. Koblizek T.I., Weiss C., Yancopoulos G.D., Deutsch U., and Risau W. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol 8 (1998) 529-532
35. Papapetropoulos A., Garcia-Cardena G., Dengler T.J., Maisonpierre P.C., Yancopoulos G.D., and Sessa W.C. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 79 (1999) 213-223
36. Hayes A.J., Huang W.Q., Yu J., Maisonpierre P.C., Liu A., Kern F.G., et al. Expression and function of angiopoietin-1 in breast cancer. Br J Cancer 83 (2000) 1154-1160
37. Stoeltzing O., Ahmad S.A., Liu W., McCarty M.F., Wey J.S., Parikh A.A., et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 63 (2003) 3370-3377
38. Ding H., Roncari L., Wu X., Lau N., Shannon P., Nagy A., et al. Expression and hypoxic regulation of angiopoietins in human astrocytomas. Neuro Oncol 3 (2001) 1-10
39. Reinmuth N., Piegelbrock E., Raedel M., Fehrmann N., Hintelmann H., Wagner R., et al. Prognostic significance of vessel architecture and vascular stability in non-small cell lung cancer. Lung Cancer 55 (2007) 53-60